GU Cancers 2026 | Prostate cancer at ASCO GU 2026: PEACE-3, BRCAAway, and T-cell engagers
Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, provides an overview of influential prostate cancer trials from ASCO GU 2026, highlighting the promising results from Phase III EORTC 1333/PEACE-3 trial (NCT02194842) of radium-223 with enzalutamide versus enzalutamide alone, as well as the BRCAAway trial (NCT03012321) assessing olaparib and abiraterone for BRCA2. Additional topics of interest include novel therapies, such as T-cell engagers and antibody drug conjugates targeting B7H3. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In prostate cancer, we saw some really good updates from Phase III, enzalutamide and radium, as well as from BRCA2, which is a combination of olaparib and abiraterone. But what was really exciting to me was some of the newer technologies and novel therapies that are coming through. So we saw some really great, interesting data from a T-cell engager in the rapid oral session, as well as there’s multiple antibody drug conjugates now targeting things like B7H3 that’s highly expressed in castration-resistant prostate cancer...
In prostate cancer, we saw some really good updates from Phase III, enzalutamide and radium, as well as from BRCA2, which is a combination of olaparib and abiraterone. But what was really exciting to me was some of the newer technologies and novel therapies that are coming through. So we saw some really great, interesting data from a T-cell engager in the rapid oral session, as well as there’s multiple antibody drug conjugates now targeting things like B7H3 that’s highly expressed in castration-resistant prostate cancer. And so I think the more novel therapeutics and more new mechanisms that we have to target in prostate cancer, the better we’ll be able to sequence our treatments going forward. So I’m really looking forward to seeing those earlier phase trials come out into registrational trials and the ongoing efforts that we all have for these registrational trials across the board. So I’m sure more to come in these new therapeutics, but it was really good to see those early signals.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
